Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myeloma treatment escalation and de-escalation trial for transplant-eligible newly diagnosed patients
ISRCTN46841867Phase 3Active, not recruiting
- Sponsor
- University of Leeds
- Start
- May 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of isatuximab, lenalidomide, bortezomib, dexamethasone, cyclophosphamide and 1 more in multiple myeloma (MM) (10 arms), sponsored by University of Leeds. Primary endpoints: Progression-free survival for Randomisation 1, Attainment of MRD negativity for Randomisation 2 and 2 more. Started May 2021; status: active, not recruiting.
02
Drugs
isatuximablenalidomidebortezomibdexamethasonecyclophosphamide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ISRCTN46841867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN46841867.